CI vs HUM

For growth investors, Cigna Corporation (CI) is the stronger pick with 11.

3% revenue growth year-over-year, versus 10. 1% for Humana Inc. (HUM). Cigna Corporation (CI) offers the better valuation at 12. 4x trailing P/E (9. 1x forward), making it the more compelling value choice. Analysts rate Cigna Corporation (CI) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.

4x versus Humana Inc. at 24. 3x. On forward P/E, Cigna Corporation is actually cheaper at 9. 1x.

Over the past 5 years, Cigna Corporation (CI) delivered a total return of +16.

6%, compared to -44. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: CI returned +124. 1% versus HUM's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cigna Corporation (CI) is the lower-risk stock at 0.

35β versus Humana Inc. 's 0. 56β — meaning HUM is approximately 59% more volatile than CI relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 75% for Cigna Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cigna Corporation (CI) is pulling ahead at 11.

3% versus 10. 1% for Humana Inc. (HUM). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -1. 4% for Humana Inc.. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cigna Corporation (CI) is the more profitable company, earning 2.

2% net margin versus 0. 9% for Humana Inc. — meaning it keeps 2. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CI leads at 3. 3% versus 1. 1% for HUM. At the gross margin level — before operating expenses — HUM leads at 14. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Cigna Corporation (CI) trades at 9.

1x forward P/E versus 26. 8x for Humana Inc. — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CI: 19. 0% to $328. 00.

All stocks in this comparison pay dividends.

Cigna Corporation (CI) offers the highest yield at 2. 2%, versus 1. 5% for Humana Inc. (HUM).

For long-horizon retirement investors, Cigna Corporation (CI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

35), 2. 2% yield, +124. 1% 10Y return). Both have compounded well over 10 years (CI: +124. 1%, HUM: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CI is a mid-cap deep-value stock; HUM is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.